Psy54 - Budget Impact Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in Turkey

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2017English

Efficacy and Safety of Nintedanib in Patients With Advanced Idiopathic Pulmonary Fibrosis

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2020English

Remarkable Improvement in a Patient With Idiopathic Pulmonary Fibrosis After Treatment With Nintedanib

Internal Medicine
Internal MedicineMedicine
2019English

Idiopathic Pulmonary Fibrosis

Pulmonologiya
PulmonaryRespiratory Medicine
2015English

Impact of Comorbidities on Mortality in Patients With Idiopathic Pulmonary Fibrosis

PLoS ONE
Multidisciplinary
2016English

Idiopathic Pulmonary Fibrosis

2020English

Psy105 - Cost-Utility of Nintedanib Versus Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis: A Belgian Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Managing Comorbidities in Idiopathic Pulmonary Fibrosis

International Journal of General Medicine
Medicine
2015English

Cell Therapy in Idiopathic Pulmonary Fibrosis†

Medical Sciences
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy